Paxlovid effective in reducing COVID-19 hospitalization among vaccinated adults 50 and over brighamwomens AnnalsofIM
However, little was known at the time about whether Paxlovid could significantly benefit vaccinated individuals, or individuals infected with novel variants of SARS-CoV-2 that were not dominant during the drug's clinical trials.
"The observed rate of hospitalization or death was low among outpatients diagnosed with COVID-19, but we found that Paxlovid was still associated with a proportional reduction of risk for hospitalization of about 50 percent across patient groups with different baseline risk levels.
"Though a prospective, randomized controlled trial is the gold standard for analyzing efficacy of medications, in a pandemic setting, we've been challenged with the need to produce rigorous data to direct clinical care in a much shorter time period," said senior author Ann Woolley, MD, MPH, Associate Clinical Director of Transplant Infectious Diseases at Brigham and Women's Hospital.
Using data from the Mass General Brigham Enclave allowed researchers to swiftly evaluate the efficacy of the drug soon after its authorization for use. The results from this study were first available to the public as a pre-print in June 2022 and were incorporated into the U.S. Centers for Disease Control's guidance on treating COVID-19. Other studies have emerged confirming the efficacy of Paxlovid, but this one has the longest study period with a very large reliable, curated dataset.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Nasal COVID-19 vaccine approved for use as booster in IndiaA nasal COVID-19 vaccine based on technology licensed from Washington University in St. Louis has been approved for emergency use in India as a booster for people who have already received two doses of other COVID-19 vaccines. The approval follows the Indian government's emergency use authorization in September of the vaccine as a primary series of two doses, and makes the intranasal vaccine the world's first to receive approval as both a primary vaccine for COVID-19 and a booster.
Read more »
Bioengineered soluble ACE2 for brain protection against SARS-CoV-2 infectionBioengineered soluble ACE2 for brain protection against SARS-CoV-2 infection biorxivpreprint NorthwesternU ChariteBerlin UChicago brain SARSCoV2 ACE2 COVID19 coronavirus covid
Read more »
What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals?What are the patterns of symptoms and risk factors for Long COVID among SARS-CoV-2 infected individuals? medrxivpreprint UUtah UCSF DukeMedSchool nyugrossman symptoms riskfactor longcovid covid COVID19 SARSCoV2
Read more »
The two Lancashire neighbourhoods where Covid infections are rocketingWith positive tests on the rise across the country but Covid deaths dropping, the picture across our region is mixed and shows two districts with huge rises in the week ending December 3
Read more »
The benefit-risk of the mRNA-1273 COVID-19 vaccineThe benefit-risk of the mRNA-1273 COVID-19 vaccine medrxivpreprint US_FDA mRNA vaccine vaccination COVID19 coronavirus covid SARSCoV2
Read more »
Two million COVID-19 vaccinations in two years for LincolnshireA significant milestone on the week of a big anniversary
Read more »